Table 1.
Baseline characteristics by treatment group.
Fig 1.
Cumulative probabilities of complete virologic suppression and virologic breakthrough by treatment group.
(A) Cumulative probabilities of complete virologic suppression (defined as HBV DNA level <20 IU/mL) during the treatment period are shown for each group. (B) Cumulative probabilities of virologic breakthrough (defined as an increase in HBV DNA level >1 log10 IU/mL) during the treatment period, are shown for each group. TDF, tenofovir disoproxil fumarate; ETV, entecavir.
Table 2.
Univariate and multivariate analyses of factors associated with complete virologic suppression.
Table 3.
Univariate and multivariate analyses of factors associated with virologic breakthrough.